Reduction of the CD16-CD56bright NK cell subset precedes NK cell dysfunction in prostate cancer

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Koo, Kyo Chul ^a   Shim, Doo Hee ^a   Yang, Chang Mo ^a   Lee, Saet Byul ^a   Kim, Shi Mun ^b   Shin, Tae Young ^a   Kim, Kwang Hyun ^a   Yoon, Ho Geun ^a   Rha, Koon Ho ^a   Lee, Jae Myun ^a   Hong, Sung Joon ^a  

^a Yonsei University College of Medicine   (South Korea)

^b ATGen   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; GAMMA INTERFERON; FC RECEPTOR; FCGR3B PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; NCAM1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ANTIGEN EXPRESSION; AREA UNDER THE CURVE; ARTICLE; CANCER GROWTH; CANCER STAGING; CD16+ CD56 DIM NATURAL KILLER CELL; CD16- CD56 BRIGHT NATURAL KILLER CELL; CD56 BRIGHT NATURAL KILLER CELL; CD56+ CD3- NATURAL KILLER CELL; CELL DAMAGE; CELL POPULATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOTOXICITY; FLOW CYTOMETER; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREGULATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; NATURAL KILLER CELL DYSFUNCTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSPECTIVE STUDY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; CASE CONTROL STUDY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR;

ANTIGENS, CD56; CASE-CONTROL STUDIES; GPI-LINKED PROTEINS; HUMANS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RECEPTORS, IGG; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84892425179     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078049     Document Type: Article

References (31)

1. Vivier E, Raulet DH, Moretta A, Caligiuri MA (2011) Innate or Adaptive Immunity? The Example of Natural Killer Cells. Science 331: 44-49.
2. Koch J, Steinle A, Watzl C, Mandelboim O (2013) Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol 34: 182-191.
3. Takahashi E, Kuranaga N, Satoh K, Habu Y, Shinomiya N, et al. (2007) Induction of CD16+ CD56bright NK cells with antitumour cytotoxicity not only from CD16- CD56bright NK Cells but also from CD16- CD56dim NK cells. Scand J Immunol 65: 126-138.
4. Cooper MA, Fehniger TA, Caligiuri MA (2001) The biology of human natural killer-cell subsets. Trends Immunol 22: 633-640.
5. Watanabe M, Kono K, Kawaguchi Y, Mizukami Y, Mimura K, et al. (2010) NK cell dysfunction with down-regulated CD16 and up-regulated CD56 molecules in patients with esophageal squamous cell carcinoma. Dis Esophagus 23: 675-681.
6. Dowell AC, Oldham KA, Bhatt RI, Lee SP, Searle PF (2012) Long-term proliferation of functional human NK cells, with conversion of CD56dim NK cells to a CD56bright phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-12. Cancer Immunol Immunother 61: 615-628.
7. Bauernhofer T, Kuss I, Henderson B, Baum AS, Whiteside TL (2003) Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer. Eur J Immunol 33: 119-24.
8. Lin CT, Yu MT, Li C, Ho YC, Shen CH, et al. (2010) Dysfunction of natural killer cells in patients with transitional cell carcinoma. Cancer Lett 291: 39-45.
9. Kim S, Iizuka K, Aguila HL, Weissman IL, Yokoyama WM (2000) In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci U S A 97: 2731-2736.
10. Takeuchi H, Maehara Y, Tokunaga E, Koga T, Kakeji Y, et al. (2001) Prognostic significance of natural killer cell activity in patients with gastric carcinoma: a multivariate analysis. Am J Gastroenterol 96: 574-578.
11. Schleypen JS, Baur N, Kammerer R, Nelson PJ, Rohrmann K, et al. (2006) Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin Cancer Res 12: 718-725.
12. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L (2012) Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 12: 239-252.
13. Klein EA, Silverman R (2008) Inflammation, infection, and prostate cancer. Curr Opin Urol 18: 315-319.
14. Basch E, Oliver TK, Vickers A, Thompson I, Kantoff P, et al. (2012) Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol 30: 3020-3025.
15. Oikawa T, Kawai K, Ishiwata I, Ohno T, Akaza H (2003) Induction of potent antitumour natural-killer cells from peripheral blood of patients with advanced prostate cancer. BJU Int 92: 1009-1015.
16. Kastelan M, Kraljic I, Tarle M (1992) NK cell activity in treated prostate cancer patients as a probe for circulating tumor cells: hormone regulatory effects in vivo. Prostate 21: 111-120.
17. Sotosek S, Sotosek Tokmadzic V, Mrakovcic-Sutic I, Thomas MI, Dominovic M, et al. (2011) Comparative study of frequency of different lymphocytes subpopulation in peripheral blood of patients with prostate cancer and benign prostatic hyperplasia. Wien Klin Wochenschr 123: 718-725.
18. Ebelt K, Babaryka G, Figel AM, Pohla H, Buchner A, et al. (2008) Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma. Prostate 68: 1-10.
19. Wagenlehner FM, Elkahwaji JE, Algaba F, Bjerklund-Johansen T, Naber KG (2007) Hartung R, Weidner W. The role of inflammation and infection in the pathogenesis of prostate carcinoma. BJU Int 100: 733-737.
20. Harlin H, Hanson M, Johansson CC, Sakurai D, Poschke I, et al. (2007) The CD16- CD56bright NK cell subset is resistant to reactive oxygen species produced by activated granulocytes and has higher antioxidative capacity than the CD16+ CD56dim subset. J Immunol 179: 4513-4519.
21. Zaidi MR, Merlino G (2011) The two faces of interferon-gamma in cancer. Clin Cancer Res 17: 6118-6124.
22. Poli A, Michel T, Theresine M, Andres E, Hentges F, et al. (2009) CD56bright natural killer (NK) cells: an important NK cell subset. Immunology 126: 458-465.
23. Izawa S, Kono K, Mimura K, Kawaguchi Y, Watanabe M, et al. H2O2 production within tumor microenvironment inversely correlated with infiltration of CD56dim NK cells in gastric and esophageal cancer: possible mechanisms of NK cell dysfunction. Cancer Immunol Immunother 60: 1801-1810.
24. Chan A, Hong DL, Atzberger A, Kollnberger S, Filer AD, et al. (2007) CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. J Immunol 179: 89-94.
25. Ferlazzo G, Munz C (2004) NK cell compartments and their activation by dendritic cells. J Immunol 172: 1333-1339.
26. Sheikhi A, Saadati K, Salmani R, Yahaghi N, Siemens DR (2011) In vitro modulation of natural killer activity of human peripheral blood mononuclear cells against prostate tumor cell line. Immunopharmacol Immunotoxicol 33: 700-708.
27. Rabinovich GA, Gabrilovich D, Sotomayor EM (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25: 267-296.
28. Yamaguchi Y, Takashima I, Funakoshi M, Kawami H, Toge T (1994) Defective natural killer activity in gastric cancer patients: possible involvement of suppressor factor receptor. In Vivo 8: 279-283.
29. Vitale M, Della Chiesa M, Carlomagno S, Romagnani C, Thiel A, et al. (2004) The small subset of CD56brightCD16- natural killer cells is selectively responsible for both cell proliferation and interferon-gamma production upon interaction with dendritic cells. Eur J Immunol 34: 1715-1722.
30. Scordamaglia F, Balsamo M, Scordamaglia A, Moretta A, Mingari MC, et al. (2008) Perturbations of natural killer cell regulatory functions in respiratory allergic diseases. J Allergy Clin Immunol 121: 479-485.
31. Schroder FH (2012) Landmarks in prostate cancer screening. BJU Int 110 Suppl 1: 3-7.